[go: up one dir, main page]

MX2019006721A - Tratamiento para la colangitis biliar primaria. - Google Patents

Tratamiento para la colangitis biliar primaria.

Info

Publication number
MX2019006721A
MX2019006721A MX2019006721A MX2019006721A MX2019006721A MX 2019006721 A MX2019006721 A MX 2019006721A MX 2019006721 A MX2019006721 A MX 2019006721A MX 2019006721 A MX2019006721 A MX 2019006721A MX 2019006721 A MX2019006721 A MX 2019006721A
Authority
MX
Mexico
Prior art keywords
treatment
primary bile
cholangitis
pbc
bile cholangitis
Prior art date
Application number
MX2019006721A
Other languages
English (en)
Other versions
MX382765B (es
Inventor
Jain Mukul
Philip Binu
Patel Pankaj
Giri Suresh
V Parmar Deven
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MX2019006721A publication Critical patent/MX2019006721A/es
Publication of MX382765B publication Critical patent/MX382765B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un compuesto terapéutico para la prevención y el tratamiento de la colangitis biliar primaria (PBC). De manera específica, la presente invención proporciona una composición farmacéutica que comprende un compuesto de la Formula (I) o una sal farmacéuticamente aceptable del mismo, para el tratamiento de la PBC. (Ver Fórmula).
MX2019006721A 2016-12-09 2017-12-08 Tratamiento para la colangitis biliar primaria. MX382765B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621042122 2016-12-09
PCT/IB2017/057746 WO2018104916A1 (en) 2016-12-09 2017-12-08 Treatment for primary biliary cholangitis

Publications (2)

Publication Number Publication Date
MX2019006721A true MX2019006721A (es) 2019-10-30
MX382765B MX382765B (es) 2025-03-13

Family

ID=60957351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006721A MX382765B (es) 2016-12-09 2017-12-08 Tratamiento para la colangitis biliar primaria.

Country Status (8)

Country Link
US (7) US20180243263A1 (es)
EP (1) EP3551180B1 (es)
JP (1) JP6840853B2 (es)
BR (1) BR112019011740A2 (es)
ES (1) ES2894261T3 (es)
MX (1) MX382765B (es)
WO (1) WO2018104916A1 (es)
ZA (1) ZA201903649B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
WO2018104916A1 (en) * 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis
CN110996966A (zh) 2017-06-05 2020-04-10 维京治疗公司 用于治疗纤维化的组合物
KR20200138283A (ko) 2018-03-22 2020-12-09 바이킹 테라퓨틱스 인코포레이티드 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
WO2020117962A1 (en) * 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
WO2022040110A2 (en) * 2020-08-18 2022-02-24 Sheng Liu Alkylating agent and combinations in the treatment of immune-related and liver diseases, alzheimer's diseases and fibrosis diseases
WO2022180612A1 (en) * 2021-02-26 2022-09-01 Cadila Healthcare Limited Orodispersible formulation of hypolipidemic agent

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
DE69331010D1 (de) 1992-07-03 2001-11-29 Smithkline Beecham Plc Benzoxazol- und benzothiazol-derivate als arzneimittel
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
DE69615016T2 (de) 1995-04-28 2002-05-02 Daiichi Pharmaceutical Co., Ltd. Pentacyclische verbindungen
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6130214A (en) 1997-10-27 2000-10-10 Dr. Reddy's Research Foundation Benzothiazin and benzoxazin derivatives; their preparation and uses
EP1073643B1 (en) 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
PL341795A1 (en) 1998-05-27 2001-05-07 Reddy Research Foundation Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds
WO2000023417A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123292A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
DK1250323T3 (da) 2000-01-19 2014-02-03 Cadila Healthcare Ltd Forbindelser med hypolipidemiske og hypokolesterolemiske virkninger, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger indeholdende dem
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001286163A1 (en) 2000-09-22 2002-04-02 Dr. Reddy's Research Foundation An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005031335A1 (ja) 2003-09-26 2005-04-07 Mitsubishi Rayon Co., Ltd. 電気泳動装置および電気泳動法並びにそれを用いた生体関連物質の検出方法
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
EP2018157A2 (en) 2006-04-26 2009-01-28 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
KR101865677B1 (ko) 2009-11-26 2018-07-16 장피트 간 질환 치료를 위한 1,3-디페닐프로프-2-엔-1-온 유도체의 용도
DE102010012223A1 (de) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Pharmazeutisches Präparat
WO2012051333A1 (en) 2010-10-12 2012-04-19 The Johns Hopkins University Antitussive compositions comprising memantine
CA2825456C (en) 2011-01-31 2016-01-05 Cadila Healthcare Limited Treatment for lipodystrophy
EP4328223A3 (en) 2011-04-22 2024-11-06 Signal Pharmaceuticals, LLC Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
US20150132289A1 (en) 2012-02-29 2015-05-14 Therapix Biosciences Ltd. Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy
SG10201607230SA (en) * 2012-06-19 2016-10-28 Intercept Pharmaceuticals Inc Preparation, Uses And Solid Forms Of Obeticholic Acid
IN2013MU01468A (es) 2013-04-22 2015-04-17 Cadila Healthcare Ltd
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (es) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02828A (es) 2013-08-29 2015-07-03 Cadila Healthcare Ltd
IN2013MU02905A (es) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
BR112017016766B1 (pt) 2015-02-06 2023-11-07 Intercept Pharmaceuticals, Inc Composição compreendendo um agonista fxr e fibrato, bem como uso para tratar doença hepática colestática
CN107530352A (zh) * 2015-03-26 2018-01-02 T3D治疗有限责任公司 使用茚满乙酸衍生物治疗肝病的方法
WO2016181409A1 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome -
WO2017064635A2 (en) * 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
WO2017089979A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic nephropathy and related diseases
WO2017089980A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic retinopathy and diabetic eye diseases
WO2018104916A1 (en) * 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis

Also Published As

Publication number Publication date
US20250041269A1 (en) 2025-02-06
US11433050B2 (en) 2022-09-06
US12178799B2 (en) 2024-12-31
JP6840853B2 (ja) 2021-03-10
EP3551180B1 (en) 2021-09-29
WO2018104916A1 (en) 2018-06-14
US20220062231A1 (en) 2022-03-03
US20210128525A1 (en) 2021-05-06
US20180243263A1 (en) 2018-08-30
ES2894261T3 (es) 2022-02-14
US11872209B2 (en) 2024-01-16
US20230255932A1 (en) 2023-08-17
US20210085644A1 (en) 2021-03-25
EP3551180A1 (en) 2019-10-16
ZA201903649B (en) 2021-01-27
JP2020502095A (ja) 2020-01-23
BR112019011740A2 (pt) 2019-10-29
MX382765B (es) 2025-03-13
US20230201162A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
DOP2019000201A (es) Compuestos inhibidores del vih
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
MX2024004439A (es) Agentes terapeuticos para enfermedades neurodegenerativas
MX2019001581A (es) Inhibidores de ssao de aminopirimidina.
MX2017009449A (es) Inhibidor jak.
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
AR101740A1 (es) Terapia de combinación y composiciones
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
CR20190361A (es) Dendrímeros terapéuticos
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
MX392470B (es) Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
SV2016005313A (es) Derivados de carboxamida
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
UY36123A (es) Derivados de carboxamida
UY36331A (es) Composición farmacéutica sólida que comprende amlodipina y losartán
MX2017003140A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
CL2019001046A1 (es) Terapia de combinación que incluye un inhibidor mdm2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cáncer. (divisional solicitud 201601131)
CU20160170A7 (es) Derivados de carboxamida